Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2025 | $35.00 | Buy | Needham |
| 5/8/2025 | $30.00 | Buy | Chardan Capital Markets |
| 3/31/2025 | $38.00 | Overweight | Piper Sandler |
| 1/7/2025 | Buy | TD Cowen | |
| 9/20/2024 | $11.00 → $26.00 | Equal-Weight → Overweight | Morgan Stanley |
| 9/19/2024 | $33.00 | Buy | B. Riley Securities |
| 7/18/2024 | $14.00 | Outperform | Oppenheimer |
| 11/15/2023 | $4.00 → $11.00 | Hold → Buy | Jefferies |
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected across all three indications this year with first-in-class potential in NT2 and IHORX142 on track to initiate first-in-human studies for the treatment of neurological and neurodegenerative disorders with clinical data in acutely sleep-deprived healthy volunteers planned for this yearORX489 advancing in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, May 14, 20
SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentation at American Society of Hematology (ASH) Annual Meeting in December 2023 ORX750: Preclinical data supporting potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders presented at World Sleep Congress; Advancing in IND-enabling studies; Clinical proof of concept data planned for 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumors BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA
Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia BEnrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment of solid tumors IND-enabling activities advancing for ORX750, an oral selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; Announces ORX750 preclinical data to be presented at World Sleep Congress in October 2023 Nominates second LockBody candidate, LB206, a conditionally bivalent PD-L1xCD3 bispecific monoclonal antibody BOSTON and LONDON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceuti
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
8-K - Centessa Pharmaceuticals plc (0001847903) (Filer)
DEFA14A - Centessa Pharmaceuticals plc (0001847903) (Filer)
144 - Centessa Pharmaceuticals plc (0001847903) (Subject)
BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years. "Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year," said Saurabh Saha MD
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen
BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody® technology platform. "We a
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
Needham initiated coverage of Centessa Pharmaceuticals with a rating of Buy and set a new price target of $35.00
Chardan Capital Markets initiated coverage of Centessa Pharmaceuticals with a rating of Buy and set a new price target of $30.00
Piper Sandler initiated coverage of Centessa Pharmaceuticals with a rating of Overweight and set a new price target of $38.00
BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2025 Global Healthcare Conference Date: June 4, 2025Fireside Chat: 11:40 AM ET Event: Goldman Sachs 46th Annual Global Healthcare ConferenceDate: June 10, 2025Fireside Chat: 9:20 AM ET Access to the live webcasts of these events, as well as archived recordings, will be available under the "Events and Publications" tab on the investor
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected across all three indications this year with first-in-class potential in NT2 and IHORX142 on track to initiate first-in-human studies for the treatment of neurological and neurodegenerative disorders with clinical data in acutely sleep-deprived healthy volunteers planned for this yearORX489 advancing in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, May 14, 20
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) well underway and on track with data expected across all three indications in 2025 with first-in-class potential in NT2 and IHORX142 in IND-enabling studies for the treatment of neurological and neurodegenerative disorders; Clinical data in acutely sleep-deprived healthy volunteers planned for 2025ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- Cent